share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024財年三季報
美股SEC公告 ·  11/14 15:47

Moomoo AI 已提取核心訊息

180 Life Sciences Corp. reported a net loss of $836,720 for the third quarter ended September 30, 2024, compared to a net loss of $10,265,760 for the same period in 2023. The decrease in net loss of $9,429,040, or 92%, was primarily due to a non-recurring impairment of IP R&D assets in the previous year. Research and development expenses decreased by 74% to $251,577, while general and administrative expenses saw a 76% reduction to $576,378. The company also reported other net income of $142,373, compared to a net expense of $9,072,598 in the prior year, largely due to the absence of the prior year's IP R&D asset impairment. As of September 30, 2024, the company had a working capital deficit of $5,158,449 and cash used in operating activities was $529,906 for the nine months...Show More
180 Life Sciences Corp. reported a net loss of $836,720 for the third quarter ended September 30, 2024, compared to a net loss of $10,265,760 for the same period in 2023. The decrease in net loss of $9,429,040, or 92%, was primarily due to a non-recurring impairment of IP R&D assets in the previous year. Research and development expenses decreased by 74% to $251,577, while general and administrative expenses saw a 76% reduction to $576,378. The company also reported other net income of $142,373, compared to a net expense of $9,072,598 in the prior year, largely due to the absence of the prior year's IP R&D asset impairment. As of September 30, 2024, the company had a working capital deficit of $5,158,449 and cash used in operating activities was $529,906 for the nine months ended September 30, 2024. The company's financial statements have been prepared on a going concern basis, with management acknowledging the need for additional funding to support operations and commercialize its iGaming assets. The company's common stock and warrants are listed on the Nasdaq Capital Market, but there is no assurance that the company will be able to maintain this listing. The company's future plans include commercializing its newly acquired online blockchain casino assets, with the goal of launching its first online casino by the end of Q1 2025.
180生命科學公司報告截至2024年9月30日的第三季度淨虧損爲836,720美元,相比之下,2023年同期淨虧損爲10,265,760美元。淨虧損減少9,429,040美元,或92%,主要是由於去年一次性對知識產權研發資產的減值。研發費用減少74%,降至251,577美元,而一般和行政費用也減少76%,降至576,378美元。該公司還報告其他淨收入爲142,373美元,而去年則爲9,072,598美元的淨支出,主要是由於去年未出現知識產權研發資產減值。截至2024年9月30日,該公司的營運資金赤字爲5,158,449美元,2024年截至9月30日的九個月內經營活動使用的現金爲529,906美...展開全部
180生命科學公司報告截至2024年9月30日的第三季度淨虧損爲836,720美元,相比之下,2023年同期淨虧損爲10,265,760美元。淨虧損減少9,429,040美元,或92%,主要是由於去年一次性對知識產權研發資產的減值。研發費用減少74%,降至251,577美元,而一般和行政費用也減少76%,降至576,378美元。該公司還報告其他淨收入爲142,373美元,而去年則爲9,072,598美元的淨支出,主要是由於去年未出現知識產權研發資產減值。截至2024年9月30日,該公司的營運資金赤字爲5,158,449美元,2024年截至9月30日的九個月內經營活動使用的現金爲529,906美元。該公司的基本報表已根據持續經營假設編制,管理層承認需要額外資金以支持運營和商業化其iGaming資產。該公司的普通股和warrants在納斯達克資本市場上市,但不能保證公司將能維持此上市。該公司的未來計劃包括商業化其新獲得的在線區塊鏈賭場資產,目標是在2025年第一季度末前推出其首個在線賭場。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息